Cue biopharma presents new positive data from phase 1 trials of cue-101 in head and neck cancer and cue-102 in wilms' tumor 1 positive cancers at sitc 2023

Boston, nov. 03, 2023 (globe newswire) -- cue biopharma, inc. (nasdaq: cue), a clinical-stage biopharmaceutical company developing a novel class of t cell engagers to selectively modulate tumor-specific t cells, announced today the presentation of new positive data from its ongoing fully enrolled phase 1 trials evaluating its lead interleukin-2 (il-2)-based t cell engager, cue-101, as a monotherapy and in combination with keytruda® (pembrolizumab) for patients with recurrent/metastatic hpv+ head and neck squamous cell carcinoma (hnscc). new clinical data will also be reported from the company's ongoing phase 1 trial evaluating its second candidate, cue-102, for the treatment of wilms' tumor 1 positive (wt1+) recurrent/metastatic cancers.
CUE Ratings Summary
CUE Quant Ranking